Zobrazeno 1 - 10
of 122
pro vyhledávání: '"N. Starodub"'
Autor:
Dr. Tetiana N. Starodub, Dr. Erik Čižmár, Andrii Kliuikov, Prof. Vladimir A. Starodub, Prof. Alexander Feher, Dr. Mariana Kozlowska
Publikováno v:
ChemistryOpen, Vol 8, Iss 7, Pp 984-988 (2019)
Abstract We report a new antiferromagnetic radical‐anion salt (RAS) formed from 7,7,8,8‐tetracyanquinonedimethane (TCNQ) anion and 2‐amino‐5‐chloro‐pyridine cation with the composition of (N−CH3−2‐NH2−5Cl−Py)(TCNQ)(CH3CN). The c
Externí odkaz:
https://doaj.org/article/ce9954cd97b74c8cb58ef775d036d4bb
Autor:
Denis M. Chudak, Olga N. Kazheva, Irina D. Kosenko, Gennady V. Shilov, Igor B. Sivaev, Georgy G. Abashev, Elena V. Shklyaeva, Lev I. Buravov, Dmitry N. Pevtsov, Tatiana N. Starodub, Vladimir I. Bregadze, Oleg A. Dyachenko
Publikováno v:
Crystals, Vol 11, Iss 9, p 1118 (2021)
New radical-cation salts based on tetramethyltetrathiafulvalene (TMTTF) and tetramethyltetraselenefulvalene (TMsTSF) with metallacarborane anions (TMTTF)[3,3′-Cr(1,2-C2B9H11)2], (TMTTF)[3,3′-Fe(1,2-C2B9H11)2], and (TMTSF)2[3,3′-Cr(1,2-C2B9H11)2
Externí odkaz:
https://doaj.org/article/a3b9fe5dc9254399aeaabd7894f23550
Publikováno v:
Crystallography Reports. 67:356-363
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12b340efdcc6ab96ccbb3f8a05c7e188
https://doi.org/10.1134/s1063774522030191
https://doi.org/10.1134/s1063774522030191
Publikováno v:
Crystallography Reports. 67:188-192
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b9b5c292f0d2ff49e7a5e283a72641d
https://doi.org/10.1134/s1063774522020195
https://doi.org/10.1134/s1063774522020195
Autor:
David M. Goldenberg, Robert M. Sharkey, Steven A. Hamburger, William A. Wegener, Pius P. Maliakal, Serengulam V. Govindan, Sajeve S. Thomas, Linda T. Vahdat, Vincent J. Picozzi, Michael J. Guarino, Manish A. Shah, Allyson J. Ocean, Alexander N. Starodub
Purpose: Sacituzumab govitecan (IMMU-132) is an antibody–drug conjugate (ADC) targeting Trop-2, a surface glycoprotein expressed on many epithelial tumors, for delivery of SN-38, the active metabolite of irinotecan. This phase I trial evaluated thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b1720f9bb447ea9eda94114d5c9e67d
https://doi.org/10.1158/1078-0432.c.6523517
https://doi.org/10.1158/1078-0432.c.6523517
Autor:
David M. Goldenberg, Robert M. Sharkey, William A. Wegener, Boyd Mudenda, Pius P. Maliakal, Serengulam V. Govindan, Wells A. Messersmith, Ronald Scheff, Kevin Kalinsky, Leena Gandhi, Tirrell Johnson, Allyson Ocean, Bryan J. Schneider, Charles J. Schneider, Jamal Misleh, Michael J. Guarino, W. Thomas Purcell, Gregory A. Masters, Ebenezer A. Kio, D. Ross Camidge, Alexander N. Starodub, Rebecca S. Heist, Jhanelle E. Gray
Purpose: We evaluated a Trop-2–targeting antibody conjugated with SN-38 in metastatic small cell lung cancer (mSCLC) patients.Experimental Design: Sacituzumab govitecan was studied in patients with pretreated (median, 2; range, 1–7) mSCLC who rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85d3221b48c4ae9f44d5518d04b2e195
https://doi.org/10.1158/1078-0432.c.6526244.v1
https://doi.org/10.1158/1078-0432.c.6526244.v1
Autor:
David M. Goldenberg, Robert M. Sharkey, Steven A. Hamburger, William A. Wegener, Pius P. Maliakal, Serengulam V. Govindan, Sajeve S. Thomas, Linda T. Vahdat, Vincent J. Picozzi, Michael J. Guarino, Manish A. Shah, Allyson J. Ocean, Alexander N. Starodub
Serum concentration of intact sacituzumab govitecan and hRS7 IgG taken 30 min after injection for each of the 4 dose levels tested.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2455a3d85f2cadfc9c90464a485cb5fc
https://doi.org/10.1158/1078-0432.22457147
https://doi.org/10.1158/1078-0432.22457147
Autor:
Michael A. Carducci, Andrew J. Armstrong, Guan Xing, Brian D. Koh, Alexander N. Starodub, Rahul Aggarwal
Purpose:A phase Ib study (1604) was conducted to evaluate the safety and efficacy of GS-5829, an oral bromodomain and extraterminal inhibitor, alone and in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC). A ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06c044b0aa65397f64f788bd43a85bca
https://doi.org/10.1158/1078-0432.c.6532548.v1
https://doi.org/10.1158/1078-0432.c.6532548.v1
Autor:
Michael A. Carducci, Andrew J. Armstrong, Guan Xing, Brian D. Koh, Alexander N. Starodub, Rahul Aggarwal
Supplementary Data from Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07fce126d60fc90b622b7d27818e719c
https://doi.org/10.1158/1078-0432.22487574.v1
https://doi.org/10.1158/1078-0432.22487574.v1
Autor:
David M. Goldenberg, Robert M. Sharkey, Steven A. Hamburger, William A. Wegener, Pius P. Maliakal, Serengulam V. Govindan, Sajeve S. Thomas, Linda T. Vahdat, Vincent J. Picozzi, Michael J. Guarino, Manish A. Shah, Allyson J. Ocean, Alexander N. Starodub
This file contains additional methods, including eligibility criteria, study design, pharmacokinetics and immunogenicity, and immunohistology, as well as additional results related to several notable patient narratives.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c35566f1635eeaa794737d1de0e61a4
https://doi.org/10.1158/1078-0432.22457150
https://doi.org/10.1158/1078-0432.22457150